Prazer Therapeutics
Latest round
- Series B
Last raised
- Apr 2025
Total raised
- $35M
Investors
- 9
About Prazer Therapeutics
Prazer Therapeutics Inc. is focused on developing innovative therapeutics for refractory diseases, utilizing proprietary technologies to target previously undruggable protein aggregates and inflammatory conditions, enhancing patient care. Prazer Therapeutics Inc. specializes in creating novel treatments for complex diseases through its proprietary technologies. Founded in 2019, the company operates out of Seoul, South Korea.Prazer Therapeutics specializes in the development of innovative therapeutics aimed at treating refractory diseases, focusing on drugging previously undruggable targets. The company’s core product offerings center around its proprietary SPiDEM™ technology, designed to degrade target proteins through small molecules. These small molecules target protein aggregates and inflammatory proteins, with applications in neurodegenerative and refractory inflammatory diseases.The revenue generation model of Prazer Therapeutics is based on collaborative partnerships and potential licensing agreements for its SPiDEM™ technology and related therapeutics. The company engages in business-to-business transactions with pharmaceutical companies and research institutions, deriving revenue from milestone payments, royalties, and research collaborations that fund ongoing development efforts. Specific financial figures and pricing plans have not been disclosed, but the company’s strategic focus on therapeutic advancements positions it to leverage the growing demand for effective treatments in the healthcare market.
Who invested in Prazer Therapeutics
9 investors across 2 rounds
See all investors in Prazer Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Prazer Therapeutics
Who invested in Prazer Therapeutics?
Prazer Therapeutics has 9 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Prazer Therapeutics raised?
Prazer Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Prazer Therapeutics last raise money?
Prazer Therapeutics's most recent round on record is a Series B, in Apr 2025.
What does Prazer Therapeutics do?
Prazer Therapeutics is a biotechnology company.
Where is Prazer Therapeutics headquartered?
Prazer Therapeutics is headquartered in Seoul, South Korea.
Which VCs invest in companies like Prazer Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Prazer Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Prazer Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.